search
Back to results

RALPPS Venus ALPPS for Hepatocellular Carcinoma

Primary Purpose

Hepatocellular Carcinoma

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
RALPPS
ALPPS
Sponsored by
Southwest Hospital, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Carcinoma focused on measuring RFA, ALPPS, hepatectomy, morbidity and mortality

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • An insufficient future liver remnant(FLR<30% in normal hepatic function or FLR<40% with hepatic cirrhosis or after chemotherapy)
  • Liver function of Child-Pugh Class A or B.
  • Liver Reserve Function:ICG-R15≤10%
  • No evidence of coagulopathy: platelet count > 50 × 109/L and a prolonged prothrombin time of < 5 seconds.

Exclusion Criteria:

  • Patients met the inclusion criteria but declined to participate.
  • Patients with severe portal hypertension, a history of esophageal variceal hemorrhage, severe hypersplenism syndrome, or refractory ascites.
  • Main portal vein、inferior vena cava、common hepatic duct and hepatic vein have tumor thrombus.
  • Extrahepatic or lymph node metastasis

Sites / Locations

  • Institute of hepatobiliary surgery,Southwest HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

ALPPS

RALPPS

Arm Description

Using ALPPS for the the treatment of hepatocellular carcinoma.

Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I(RALPPS).Habib 4X was used in RFA.

Outcomes

Primary Outcome Measures

morbidity during perioperation
complications include bile leakage, abdominal infection, hemorrhage, PHLF e.t.
mortality during perioperation

Secondary Outcome Measures

Full Information

First Posted
November 17, 2014
Last Updated
November 30, 2015
Sponsor
Southwest Hospital, China
search

1. Study Identification

Unique Protocol Identification Number
NCT02299843
Brief Title
RALPPS Venus ALPPS for Hepatocellular Carcinoma
Official Title
A Prospective Randomized Controlled Trial of Radio-frequency Assisted ALPPS(RALPPS)and Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy(ALPPS)in the Treatment of Hepatocellular Carcinoma.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2015
Overall Recruitment Status
Unknown status
Study Start Date
October 2014 (undefined)
Primary Completion Date
November 2016 (Anticipated)
Study Completion Date
December 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Southwest Hospital, China

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Currently,the "ALPPS" (associating liver partition with portal vein ligation for staged hepatectomy) procedure which enables the rapid growth of the future liver remnant and extends surgical indication to patients with mid-advanced stage hepatocellular carcinoma becomes a research hot spot. However, the procedure has a high morbidity and mortality rate.Using radio-frequency ablation instead of in-situ split of liver to avoid forming a coagulation band in stage I will reduce the incidence of complications(bile leakage, abdominal infection,hemorrhage e.t.) The investigators named this technique as Radio-frequency Assisted Liver Partition with Portal vein ligation for staged hepatectomy (RALPPS).Investigators hypothesized that the RALPPS might result in lower morbidity and mortality rate than ALPPS in the treatment of hepatocellular carcinoma . This Prospective Randomized Controlled Trial is on the Safety and Efficacy of radio-frequency assisted liver partition with portal vein ligation for staged hepatectomy for hepatocellular carcinoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma
Keywords
RFA, ALPPS, hepatectomy, morbidity and mortality

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ALPPS
Arm Type
Active Comparator
Arm Description
Using ALPPS for the the treatment of hepatocellular carcinoma.
Arm Title
RALPPS
Arm Type
Experimental
Arm Description
Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I(RALPPS).Habib 4X was used in RFA.
Intervention Type
Procedure
Intervention Name(s)
RALPPS
Intervention Description
Using radiofrequency ablation assisted ALPPS(RALPPS)instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
Intervention Type
Procedure
Intervention Name(s)
ALPPS
Intervention Description
Treat the hepatocellular carcinoma with ALPPS.
Primary Outcome Measure Information:
Title
morbidity during perioperation
Description
complications include bile leakage, abdominal infection, hemorrhage, PHLF e.t.
Time Frame
2 years
Title
mortality during perioperation
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: An insufficient future liver remnant(FLR<30% in normal hepatic function or FLR<40% with hepatic cirrhosis or after chemotherapy) Liver function of Child-Pugh Class A or B. Liver Reserve Function:ICG-R15≤10% No evidence of coagulopathy: platelet count > 50 × 109/L and a prolonged prothrombin time of < 5 seconds. Exclusion Criteria: Patients met the inclusion criteria but declined to participate. Patients with severe portal hypertension, a history of esophageal variceal hemorrhage, severe hypersplenism syndrome, or refractory ascites. Main portal vein、inferior vena cava、common hepatic duct and hepatic vein have tumor thrombus. Extrahepatic or lymph node metastasis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jun Yan, Ph.D
Phone
+86-23-18502327600
Email
yanjun@sina.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kuansheng Ma, Ph.D
Organizational Affiliation
Institute of hepatobiliary surgery,Southwest Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Institute of hepatobiliary surgery,Southwest Hospital
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400038
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Yan, Ph.D
Phone
+86-23-18502327600
Email
yanjun@sina.cn
First Name & Middle Initial & Last Name & Degree
Jun Yan, Ph.D

12. IPD Sharing Statement

Learn more about this trial

RALPPS Venus ALPPS for Hepatocellular Carcinoma

We'll reach out to this number within 24 hrs